Impact of baseline telomere length on survival and chemotherapy related toxicity in breast cancer patients receiving (neo)adjuvant anthracycline containing chemotherapy.

The aim of this study is to assess baseline mean leukocyte telomere length (TL) as a potential predictive factor for chemotherapy toxicity and a prognostic marker for long-term outcome in early breast cancer (BC) patients. 445 BC patients were selected, diagnosed between 2007 and 2010 with early BC and treated with (neo)adjuvant fluorouracil, epirubicin and cyclophosphamide (FEC) or with FEC and Docetaxel (FEC-D). RT-qPCR was performed on germline DNA samples collected at diagnosis before any treatment, to measure mean leukocyte TL. Uni- and multivariable logistic regression or Cox proportional hazard regression analyses were carried out to assess correlation between baseline TL and toxicity parameters (derived from the medical chart) or longer-term outcome. Baseline TL correlated with age as expected (p = 0.005), but not with febrile neutropenia (n = 97), left ventricular ejection fraction >10% decrease (n = 17) nor other toxicity endpoints measured (all p > 0.05). TL was neither associated with overall survival, breast cancer specific survival or distant disease-free survival (all p > 0.05). Baseline TL is not associated with chemotherapy-related toxicity nor long-term outcome in BC patients.

Informations de copyright

Copyright © 2022. Published by Elsevier Inc.

Déclaration de conflit d'intérêts

Declaration of Competing Interest Hans Wildiers's institution received financial compensation on his behalf for advisory boards, lecture fees and/or consultancy fees from Immutep Pty, MSD, Astrazenca Ireland, Daiichi, AbbVie, Lilly, PSI CRO AG, KCE, EISAI, Astrazeneca, Roche. Hans Wildiers's institution received an unrestricted research grant on his behalf from Roche and he received travel support from Pfizer and Roche. Christof Vulsteke: Research funding paid to institution from Merck MSD; Consulting fees from GSK, Astellas Pharma, Merck MSD, BMS, Leo-Pharma, Janssen, Cilag, Bayer, and AstraZeneca. Kevin Punie received honoraria for consultancy/advisory roles or speaker fees from Astra Zeneca, Eli Lilly, Gilead Sciences, MSD, Novartis, Roche, Seagon (personal, outside the submitted work). Kevin Punie's Institution received honoraria for consultancy/advisory roles or speaker fees from Astra Zeneca, Eli Lilly, Gilead Sciences, Medscape, MSD, Mundi Pharma, Novartis, Pfizer, Pierre Fabre, Roche, Seagen, Teva, Vifor Pharma (paid to institution, outside the submitted work). Research funding from MSD and Sanofi (paid to institution, outside the submitted work). Travel support from Astra Zeneca, Novartis, Pfizer, PharmaMar, Roche (outside the submitted work).